Compare Organon & Co. Common Stock (OGN) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Vital Farms Inc — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Vital Farms Inc trades at $8.92 (market cap $400.98M). The key difference: Organon & Co. Common Stock is far larger — about 9× Vital Farms Inc's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Vital Farms Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Vital Farms Inc for 15 Days on average.
| OGN | VITL | |
|---|---|---|
Market Cap | $3.62B | $400.98M |
Volume | 2,892,999 | 1,181,598 |
Sector | Health | Consumer Staples |
52-Week High | $13.81 | $40.85 |
52-Week Low | $5.70 | $8.28 |
Typical Hold Time | 0 Days | 15 Days |
Enterprise Value | $11.04B | $487.99M |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Vital Farms (VITL) trades at $9.34, down 1.37% amid bearish technical signals and challenging fundamentals. The stock faces pressure from declining earnings, with Q1 2026 missing expectations and Q3 2026 expected at -$0.13 EPS. Despite a 56% analyst buy rating and $13.11 consensus target, recent news highlights strategic review discussions and pricing pressures in the egg market. Revenue remains flat at $766M for 2026 with net margins collapsing to near-zero, while cash flow trends show significant operational challenges.
The outlook remains cautious with near-term headwinds from industry oversupply and margin compression. Investment opportunity exists if strategic options materialize, but risks include sustained profitability challenges and competitive pressures. Current valuation metrics suggest potential upside if execution improves, but investors should monitor Q3 earnings and strategic developments closely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
